Comprehensive FDA Inspection Preparation and Quality System Enhancement for Combination Product Implant Manufacturing

1. Background and situation

A European manufacturer producing a long-term implant combination product containing an antibiotic faced its first FDA inspection. The product was classified by the FDA as a combination product requiring compliance with both device and pharmaceutical regulations. The manufacturer already maintained an EN ISO 13485:2013 compliant quality system and conducted part of manufacturing in a clean room environment, including sterile catheter packaging and aseptic filling processes to assemble the final combination product. Additional quality support was requested to evaluate current compliance levels and upgrade the system to ensure full readiness for the FDA audit.

2. Key challenges faced

The manufacturer needed to maintain a quality system that simultaneously satisfied 21 CFR 820 Quality System Regulations for medical devices and 21 CFR 211 Good Manufacturing Practices for finished pharmaceuticals. Combination product companies must address both regulatory frameworks, and discrepancies among the various regulations and standards required careful identification and resolution. The existing quality system, while certified under the 2013 version of EN ISO 13485, needed updates to align with the 2016 version and to close gaps that could impact FDA expectations during the inspection.

3. Strategic approach to preparation

The preparation program was completed within three months and included acting as the manufacturer’s U.S. Agent. A baseline audit of operations was performed using 21 CFR 820 and 21 CFR 211 as reference standards. Education was provided on the specific requirements of EN ISO 13485 and the dual regulations. The quality system was systematically transitioned from EN ISO 13485:2013 to the 2016 version. A detailed gap analysis identified all areas requiring improvement across the entire quality system.

4. Specific actions and quality system enhancements

Significant updates were made to design control, corrective and preventive action (CAPA), and process validation systems to address identified gaps. Updated procedures, work instructions, and forms were drafted and implemented. The quality system documents were revised to ensure alignment with both device and pharmaceutical regulatory expectations while preserving operational efficiency. All changes were verified through internal reviews to confirm effectiveness before the FDA arrival.

5. Technical file and design history file reconstruction

A comprehensive audit of the existing Design History File (DHF) was conducted, followed by full reconstruction using standardized templates and verified source documentation. The rebuilt DHF incorporated all required elements for both medical device and pharmaceutical compliance. Outdated or irrelevant information was removed, and the file was organized to facilitate efficient FDA review during the inspection.

6. Inspection support and facilitation

The support team attended the FDA inspection on-site and facilitated clear, effective communication between the manufacturer and FDA inspectors throughout the audit and in all follow-up activities. Pre-inspection preparation ensured all personnel were ready to respond accurately and promptly to inspector questions.

7. Outcomes and post-inspection benefits

The FDA inspection resulted in only four minor observations and a Voluntary Action Indicated (VAI) rating, representing an exceptionally successful outcome for a first-time inspection of a combination product facility. The manufacturer achieved full compliance with dual regulatory requirements. The enhanced quality system provided a stronger foundation for ongoing operations, reduced risk of future audit findings, and demonstrated effective continuous improvement. The project established efficient processes that balanced strict compliance with practical manufacturing needs and positioned the manufacturer for sustained success in the U.S. market.